Emerging and mid-sized pharmaceutical companies face multiple constraints when it comes to commercializing their products in an increasingly complex commercial ecosystem. They often do not possess the elaborate commercial infrastructure that typical Big Pharma does and find it difficult to dedicate resources, both talent and capital, towards the efficient commercialization of their products.